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Diabetic cardiomyopathy is defined as ventricular dysfunction initiated by alterations in cardiac energy substrates in
the absence of coronary artery disease and hypertension. In addition to the demonstrated burden of cardiovascular
events associated with diabetes, diabetic cardiomyopathy partly explains why diabetic patients are subject to
a greater risk of heart failure and a worse outcome after myocardial ischemia. The raising prevalence and
accumulating costs of cardiovascular disease in diabetic patients underscore the deficiencies of tertiary prevention
and call for a shift in medical treatment. It is becoming increasingly clearer that the effective prevention and
treatment of diabetic cardiomyopathy require measures to regulate the metabolic derangement occurring in the
heart rather than merely restoring suitable systemic parameters. Recent research has provided deeper insight into
the metabolic etiology of diabetic cardiomyopathy and numerous heart-specific targets that may substitute or
reinforce current strategies. From both experimental and translational perspectives, in this review we first discuss
the progress made with conventional therapies, and then focus on the need for prospective metabolic targets that
may avert myocardial vulnerability and functional decline in next-generation diabetic care.
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As of 2013, one in ten individuals living in Western coun-
tries was diagnosed with diabetes mellitus (DM), and three
in ten were obese [1]. Epidemiological studies have long
recognized diabetes to be an independent risk factor for
heart failure (HF) and a worse prognosis after myocardial
infarction (MI) [2]. Further, imaging studies have shown
that diabetic patients are prone to ventricular hypertrophy,
diastolic dysfunction, and decreased myocardial strain.
Diabetic cardiomyopathy (DCM) encompasses the group
of diabetic patients who, while being otherwise free of car-
diovascular events, display echocardiographic abnormal-
ities ranging from mild diastolic impairment to overt heart
failure, and prevalence of DCM may be over 50% among
patients in clinical and preclinical stages [3,4]. Triggered by
insulin inefficiency, hyperglycemia and hyperlipidemia,
DCM brings out the damage of the myocardium due to* Correspondence: olorenzo@fjd.es
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article, unless otherwise stated.cell hypertrophy, steatosis, apoptosis, oxidative stress,
inflammation, fibrosis, and microtubular derangement
[5,6]. The existence of cardiac sinusoids representing
fetal vascular pattern support that the pathophysio-
logical mechanism of DCM initiates in the coronary
microcirculation due to alterations in cardiac metabol-
ism [6]. Although this phenotype has been described in
both type-I (T1DM) and type-II (T2DM) diabetic patients,
hyperglycemia-induced myocardial fibrosis may be pre-
dominant in T1DM hearts, while cardiomyocyte hyper-
trophy and steatosis are more related to the insulin
resistance and dyslipidemia of T2DM [7]. In addition, the
earlier onset of ventricular remodelling and down-
regulation of pro-survival factors in experimental female
rats but not yet in male counterparts suggests gender dif-
ferences in DCM progression [8].
Intensive glycemic goals (HbA1c <7%) have failed to
prevent cardiac complications in long-term diabetic pa-
tients or have even increased cardiovascular mortality [9].
The failure of the therapy approaches employed to date
calls for accelerating efforts towards the development ofCentral. This is an Open Access article distributed under the terms of the
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function while contributing to the overall care of diabetes.
Growing experimental research emphasizes the prospect-
ive utility of correcting the metabolic imbalance that oc-
curs in the diabetic heart.
In this work we aim to provide an updated, metabolism-
oriented overview of the main therapeutic findings on
therapy approaches for DCM. A comprehensive search of
the PubMed/MEDLINE and EMBASE databases was con-
ducted for articles published up to and including 2014
using the terms “diabetic cardiomyopathy” and “diabetes
heart” in combination with the different animal models,
drugs and related pathogenic factors to retrieve available
literature. All types of articles (e.g., original studies, ran-
domized controlled trials, review articles) published in
English and reporting on studies in animals and humans
were included.Pathobiology of diabetic cardiomyopathy
Chronic hyperglycemia is primarily elicited by insulin defi-
ciency and/or resistance and damages the myocardium by
reducing the expression of glucose transporters, by in-
creasing the expression of the pyruvate decarboxylase in-
hibitor pyruvate dehydrogenase kinase-4 (PDK4), and by
raising the flux of glucose into hexosamine, pentose and
polyol pathways. Such metabolic changes increase the
burden of advanced glycation end-products (AGEs) and
restrict energy production to fatty acid (FA) [5]. The
harmful effects of AGEs are related to their ability to ei-
ther promote collagen cross-linking and myocardial
fibrosis or activate AGE receptor (RAGE)-mediated oxi-
dative stress and pro-inflammatory nuclear factor-κB
(NF-κB) signaling. Also, derangement of lipid metabol-
ism is widely accepted as the most deleterious impact of
diabetes on the heart. FA uptake may exceed the cap-
acity for cardiac utilization and promote the deposition
of triacylglycerols (TAGs) and ceramides, thus leading
to cardiomyocyte steatosis and hypertrophy. Concur-
rently, increased FA oxidation leads to higher rates of
oxygen consumption, reactive oxygen and nitrogen spe-
cies (ROS/RNS) overproduction, endoplasmic reticulum
(ER) stress and mitochondrial uncoupling [5]. Subse-
quent mitochondrial damage and increased ROS seem
to be the main triggers for calcium mishandling, cardio-
myocyte apoptosis, and the chronic low-grade inflamma-
tion occurring in DCM [10,11]. Moreover, the pro-oxidant
status may be accentuated by defects in copper trafficking
leading to myocardial copper deficiency [12]. All these
pathogenic factors, in conjunction with many others (for
further detail, see [5]) eventually converge to generate
the progressive impairment of ventricular contractility,
and thus provide valuable therapeutic substrates for the
diabetic heart.Progress and limitations of conventional antihyperglycemic
therapies
DCM may account for a substantial fraction of idiopathic
HF diagnoses in T2DM patients, and also contribute to a
worse prognosis of HF after myocardial ischemia in these
patients. The United Kingdom Prospective Diabetes Study
34 (UKPDS 34) evaluated the outcomes of overweight
T2DM patients following tight glycemic control with met-
formin, and is the only clinical study to show reduced car-
diovascular mortality following intensive blood-glucose
control [13]. However, there is long-standing controversy
regarding the safety and efficacy of metformin in the set-
ting of HF. A recent systematic review of observational
studies involving 34,000 patients concluded that metfor-
min is at least as safe as other glucose-lowering treatments
even in the presence of reduced ejection fraction and
chronic kidney disease [14]. Ongoing trials will soon pro-
vide specific evidence on the role of metformin in T2DM
patients with HF (e.g. NCT01690091 - ClinicalTrials.gov).
A variety of preclinical studies have pointed out the cardi-
oprotective benefits of metformin on both T1DM and
T2DM animal models of DCM, an effect likely associated
with its ability to prevent cardiomyocyte oxidative stress
and apoptosis by inhibiting the respiratory complex I and
modulating specific ER stress signaling pathways (Table 1)
[15-22]. Yet, the positive outcome on T1DM models
seems more related to a dramatic reduction of plasma glu-
cose and TAGs than to a myocardial-specific response
(Table 2) [15]. Although metformin is not prescribed for
most T1DM patients, it is widely recommended as the
first-line oral therapy for T2DM. Unexpectedly, in T2DM
animals cardiac fibrosis and contractile performance to-
gether with molecular markers of inflammation were not
consistently improved or even aggravated. Such effects
challenge our knowledge of the impact on metformin in
the heart and question its utility against DCM. Of other
conventional antihyperglycemic agents, only sulfonylureas
have been proven to exert some benefit against experi-
mental DCM (Table 1) [23]. However, sulfonylureas have
been associated with an excess risk of MI and cardiovas-
cular events [13], with the only possible exception of gli-
clazide [24]. Further, the use of sulfonylureas has been
clearly restricted given their tendency to trigger hypogly-
cemias and weight gain (Table 2).
New directions in therapy against glucose-associated injury
Current trends in the care of the diabetic heart have
downgraded the importance of HbA1c and other classical
glycemic markers. However, abrogation of myocardial-
specific insulin resistance and glucose toxicity could still
be a valid strategy against DCM. Some of the most intui-
tive genetic interventions with therapeutic interest have
targeted GLUT4, the most prevalent insulin-regulated
glucose transporter in the heart, PDK4 and insulin-like
Table 1 Progress on the effects of conventional metabolic therapies in experimental DCM
Type 1 diabetes Type 2 diabetes
STZ OVE26 Akita ob/ob db/db ZDF GK DIO†
Metformin ↑Glucose utilization
↑Cardiac function
↓Apoptosis ↑Cardiac
function
↓Hypertrophy ~
Fibrosis ↑Cardiac
function
~Hypertrophy
↑Fibrosis ↓Steatosis
↓/~Hypertrophy
↓Fibrosis
↓Apoptosis ~
Oxidative stress
↑Cardiac function
Sulfonylureas ↑Cardiac function
DPP-4 inhibitors ↑Hypertrophy
↑Cardiac function
~Hypertrophy
↓Fibrosis ↓Oxidative
stress ~Cardiac
function
↓Hypertrophy
↓Fibrosis ↓Apoptosis
↑Cardiac function
GLP-1R agonists ↑Glucose utilization
↓Hypertrophy
↓Apoptosis
↓Inflammation
↑Cardiac function
Statins ↓Fibrosis ↓Oxidative
stress ↓Inflammation
↑Cardiac function
↓Hypertrophy
↓Fibrosis
↓Inflammation
↑Cardiac function
PPARα agonists ↑Glucose utilization
↓Steatosis ~ Cardiac
function
~Hypertrophy
↓Fibrosis ↓Steatosis
↑Glucose utilization
↓ER stress
↓Inflammation
↑Cardiac function
PPARγ agonists ↓Hypertrophy
↓Apoptosis
↓Steatosis
↓Oxidative stress
↑Cardiac function
↑Hypertrophy ↑Glucose utilization
~ Cardiac function
↑Glucose utilization
Reference [15,16,23,25-27] [17] [28,29] [18] [30-32] [19,33] [20,21] [34-38]
Conventional treatments against DCM have been assessed in different animal models of type-I [STZ, streptozotocin-treated mice/rats; OVE26, calmodulin transgenic mice; Akita, insulin-2 deficient mice] and type-II
[ob/ob, leptin deficient mice; db/db, leptin receptor deficient mice; ZDF, Zucker Diabetic Fatty, heterozygous leptin receptor deficient rats; GK, Goto-Kakizaki rats; DIO, diet-induced obesity] diabetes. ↑, ↓ and ~ stand for
increased, decreased or not modified effect, respectively. †For the sake of simplicity, evidence from low-dose STZ- plus diet-induced T2DM models are displayed in the DIO column. References: [34] and [37].
Fuentes-A
ntrás
et
al.Cardiovascular
D
iabetology
 (2015) 14:17 
Page
3
of
11
Table 2 Limitations and drawbacks for the use of
conventional metabolic therapies against DCM
Therapy Limitation/Drawback Reference
Metformin Dependence on plasma glucose reduction [15,19]
Inconsistent recovery of cardiac function
Potential induction of myocardial fibrosis
Sulfonylureas Higher risk of total cardiovascular events
(except gliclazide)
[13,23]
Hypoglycemia
Weight gain
DPP-4
inhibitors
Higher risk of subclinical cardiac
dysfunction and HF hospitalization
[28,30,39,40]
Inconsistent recovery of cardiac function
and remodelling
Higher risk of myocardial hypertrophy with
effective dose
GLP-1R
agonists
Lack of data from large clinical trials on
cardiovascular outcome
Statins Dependence on plasma lipid reduction
and vascular remodelling
[41,42]
Adverse impact on insulin production and
sensitivity
Higher risk of total cardiovascular events
(torcetrapib)
PPARα
agonists
Dependence on plasma lipid reduction [31,38,43]
Inconsistent recovery of cardiac function
(fenofibrate)
DCM-like phenotype by experimental
PPARα agonism
PPARγ
agonists
Dependence on plasma lipid reduction [29,44,45]
Higher risk of HF (pioglitazone)
Higher risk of total cardiovascular events
(rosiglitazone)
Inconsistent recovery of cardiac function
(rosiglitazone)
Potential induction of myocardial
hypertrophy (rosiglitazone)
DCM-like phenotype by experimental
PPARγ agonism
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proaches face the potential threat of inducing intracellular
glucose excess and associated toxicity. In this scenario,
incretins may be advantageous. Although drugs modulat-
ing the incretin system are conventional agents in the
management of diabetes, they may have more cardiopro-
tective properties than those currently known (Table 1)
[20,28,30,34-36,49]. The cardinal role of incretins (i.e.
glucagon-like peptide 1, GLP-1) is the regulation of post-
prandial glycemia by stimulating insulin secretion in a
glucose-dependent manner. Such endogenous modulation
provides an exciting advantage over conventional antihy-
perglycemic drugs. Moreover, GLP-1 receptor (GLP-1R)has been detected in large amounts in the sarcolemma of
isolated cardiomyoctes, thus suggesting that the cardiac
effects of GLP-1 may be partially driven in a myocardial,
insulin-independent, and specific fashion [20]. GLP-1 has
been shown to enhance glucose uptake and limit FA con-
sumption and lipotoxicity, likely by increasing GLUT-1
translocation and down-regulating the main cardiac FA
transporter FAT/CD36 [30,50,51]. Further, we described
anti-apoptotic/fibrotic effects of exogenous GLP-1 and its
insulinotropic inactive metabolite GLP-1(9–36) in cardio-
myocytes under diabetic conditions [20]. The first set of
drugs to be developed, dipeptidyl peptidase-4 (DPP-4) in-
hibitors, increases GLP-1 levels in a physiological range
and are weight neutral (Table 1). However, palliation of
cardiac architectural and functional alterations was incon-
sistent among different models of T2DM exposed to sita-
gliptin [20,28,30]. In addition, the Saxagliptin Assessment
of Vascular Outcomes Recorded in Patients with Diabetes
Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction
(TIMI) 53 (SAVOR-TIMI 53) trial reported a 27% increase
in hospitalization due to HF among diabetic patients who
received saxagliptin as compared with placebo, and found
no significant reductions on any macrovascular endpoint
[39]. No clear explanation has been provided for these
heterogeneous results. In this regard, DPP-4 inhibitors
may increase the circulating half-life of DPP-4, which has
been independently associated with a higher risk of car-
diac dysfunction in T2DM patients [40]. This may be ex-
plained by the ability of DPP-4 to inactivate non-incretin
molecules such as the brain natriuretic peptide, several
chemokines (i.e., SDF1), and energy-related molecules
(i.e., peptide-YY) [52]. Further, dosage might also be a
relevant drawback for at least the use of sitagliptin, given
that the improvement of glycemic control required higher
doses which in turn induced cardiac hypertrophy in ex-
perimental models (Table 2) [28]. Despite the disappoint-
ing results, DPP-4 inhibition has also elicited positive
myocardial outcomes and thus further research on its car-
dioprotective actions is warranted. For instance, sitagliptin
has been shown to increase myocardial glucose uptake
and ejection fraction in cohorts of non-diabetic patients
with non-ischemic cardiomyopathy and stable coronary
artery disease, respectively [53,54].
GLP-1R agonists may withstand some of the contro-
versy concerning DPP-4 inhibitors (Table 1). Exenatide
was recently shown to ameliorate heart performance by
increasing glucose uptake and, consistent with Randle’s
hypothesis, down-regulating FAT/CD36 in a DCM-like
model [49]. Similarly, liraglutide improved cardiac out-
come in diet- plus streptozotozin (STZ)-induced T2DM
animals independent of restoration of fasting blood
glucose [34]. Nevertheless, the mechanisms underlying
such functional recovery remain elusive and the attenu-
ation of molecular markers of myocardial remodeling
Table 3 Genetic manipulation of key metabolic mediators of DCM with prospective therapeutic relevance
Mechanism Model Year Genetic engineering Myocardial outcome Reference
Glucose-associated injury db/db 2002 Transgenic GLUT4 ↑Glucose utilization, ↑Cardiac function [46]
DIO 2011 Transgenic PDK4 ↓Steatosis [47]
STZ 2001 Transgenic IGF-1 ↓Hypertrophy, ↓Apoptosis, ↓Oxidative stress,
↑Cardiac function
[48]
STZ 2009 RAGE knockdown ↑Mitochondrial function, ↑Cardiac function [55]
STZ 2013 Transgenic GLO-1 ↓Fibrosis, ↓Oxidative stress, ↓Inflammation [56]
STZ 2005 Transgenic O-GlcNAcase ↑Ca2+ mobilization, ↑Cardiac function [57]
MHC-PPARγ 2010 PPARα knockout ↓Hypertrophy, ↓ Apoptosis, ~Steatosis, ↓Oxidative
stress, ↑Mitochondrial function, ↑Cardiac function
[58]
Lipid-associated injury DIO 2007 Transgenic PPARβ/δ ↓Steatosis [59]
MHC-PPARα 2007 FAT/CD36 knockout ↓Steatosis, ↑Glucose utilization, ~Hypertrophy,
↑Ca2+ mobilization, ↑Cardiac function
[60]
MHC-PPARα 2010 LPL knockout ↓Hypertrophy, ↓Steatosis, ↑Glucose utilization,
↑Mitochondrial function, ↑Cardiac function
[61]
STZ 2014 Perilipin-5 knockout ↓Steatosis, ↓Oxidative stress, ↑Cardiac function [62]
Akita 2013 Transgenic ATGL ↓Steatosis, ↑Glucose utilization, ↑Mitochondrial
function, ↑Cardiac function
[63]
DIO 2014 Transgenic ATGL ↓Steatosis, ↑Diastolic/Systolic function [64]
STZ 2008 Transgenic HSL ↓Fibrosis, ↓Steatosis, ↓Oxidative stress [65]
STZ 2014 Arachidonate
12/15-lypoxygenase
↓Fibrosis, ↓Oxidative stress, ↓Inflammation [66]
DIO 2012 Transgenic SCD1 ↑Steatosis, ↑Glucose utilization, ↓Oxidative stress,
↓Apoptosis
[67]
MHC-PPARγ 2012 Transgenic DGAT-1 ~Steatosis, ↑Glucose utilization, ↑Cardiac function [68]
MHC-ACS 2009 Transgenic DGAT-1 ↑Steatosis, ↓Apoptosis, ↑Glucose utilization,
↓Oxidative stress, ↑Mitochondrial function,
↑Cardiac function
[69]
DIO 2014 Transgenic Adiponectin R1 ↓Hypertrophy, ↓Steatosis, ↓Oxidative stress [70]
DIO 2013 Transgenic APPL1 ↓Steatosis, ↑Glucose utilization, ↑Cardiac function [71]
MHC-LPLGPI 2004 Transgenic human apoB ↓Steatosis, ↑Glucose utilization [72]
Metabolism-associated
inflammation
STZ 2010/13 TLR4 knockdown ↓Hypertrophy, ↓Fibrosis, ↓Apoptosis, ↓Oxidative
stress, ↑Cardiac function
[73,74]
NOD 2012 TLR4 knockout ↓Steatosis, ↑Cardiac function [75]
STZ 2014 HMGB1 knockdown ↓Hypertrophy, ↓Fibrosis, ↑Cardiac function [76]
DIO + STZ 2013 NLRP3 knockdown ↓Hypertrophy, ↓Fibrosis, ↑Cardiac function [37]
↑, ↓ and ~ stand for increased, decreased or not modified effect, respectively.
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ation [35,36]. In the clinical setting, exenatide achieved
greater benefits in glycemic control, bodyweight and
heart pressure as compared to sitagliptin or pioglitazone
when all three were used in combination with metfor-
min [77]. It is expected that the Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Out-
come Results (LEADER) trial will for the first time pro-
vide insight into the cardiovascular impact of GLP-1R-
agonists in T2DM patients. To fully assess the potential
utility of incretin-based drugs against DCM, along with
their safe contribution to the overall care of diabetes,
more evidence is needed on its clinical use and a deeperunderstanding of the direct impact on cardiomyocytes
must be attained.
Decreasing the excess of harmful AGEs is also a main
goal of glycemic control in DCM. AGEs are well-
described mediators of hyperglycemia-associated cellular
injury caused by increased reactive substrate availability.
Although there is clinical evidence that AGE disruption
may improve diastolic impairment [78], no data on such
an effect in DCM patients are available. Consistently,
RAGE ablation or cross-linking disruption in STZ-treated
animals has been shown to effectively revert cardiac dys-
function [55,79]. Main strategies to palliate AGE-induced
dysfunction are depicted in Table 3 [56,57] and may make
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all, facilitating glucose transport across the sarcolemma in
a glucose-dependent manner and avoiding its conversion
into toxic alternate products may mark a major success
against DCM.
Progress and limitations of conventional
antihyperlipidemic therapies
The unsuccessful prevention of cardiac complications in
long-term T2DM patients by glycemia-oriented therap-
ies has prompted a shift in the care of the diabetic heart.
Various clinical studies have reported an outstanding
decrease of cardiovascular risk in T2DM patients who
undergo intensive lipidemic control [80-82]. It is known
that hyperlipidemia may lead to FA accumulation and
lipotoxicity in the diabetic myocardium. Therapeutic stan-
dards for diabetic patients include the prescription of lipid
modifying agents, mainly HMG-CoA reductase inhibitors
(i.e., statins) and peroxisome proliferator-activated recep-
tor (PPAR) agonists (i.e., fibrates, glitazones), in both pri-
mary and secondary prevention. While statins are one of
the most prescribed drugs worldwide due to their effective
and safe impact on cholesterol levels, they do not seem to
affect the natural history of DCM and their repercussion
on the diabetic myocardium is currently being investi-
gated. Most animal evidence is based on STZ-treated
animals, and it has been shown that a variety of statins
successfully reverted the DCM phenotype (Table 1)
[25,26,37]. Yet it remains unclear whether the improve-
ment of cardiac performance is due mostly to decreased
vascular remodeling and heart workload rather than to
a direct cardiac effect. Major clinical shortcomings in
need of explanation include the recently reported ad-
verse impact of statins on insulin sensitivity and β-cell
function [41] and the increase of overall cardiovascular
events induced by other cholesterol-modulating therap-
ies such as the HDL raiser torcetrapib (Table 2) [42].
Nevertheless, current data do not support discontinuing
statin therapy in diabetic patients [41].
PPARs are critical regulators of lipid transport, storage
and utilization mainly by inducing the expression of
FAT/CD36, FA oxidation enzymes, and PDK4. Import-
antly, PPARs are differentially located in organic tissues:
PPARα is abundant in the heart while PPARγ is prefer-
entially found in the adipose tissue. In diabetic animals
(Table 1), pharmacological agonism of PPARα or PPARγ
alleviated the DCM phenotype, likely by normalizing myo-
cardial insulin-stimulated glucose uptake and reducing
myocardial FA misuse and accumulation [19,27,31-33,38].
However, most studies in animal models do not provide
consistent evidence that these drugs can rescue cardiac
contractile function, or whether the cardiac benefits are
rather a partial consequence of their lipid-lowering action
(Table 2) [27,29,31,32,38]. From a clinical perspective, therelative safety of widely prescribed fibrates contrasts with
the fact that PPARγ-based strategies have faced important
drawbacks. Fibrates have proved to reduce the incidence
of non-fatal MI and cardiovascular deaths in diabetic
patients [43], although their contribution was milder than
expected and further effort is needed to elucidate their
mechanistic rationale. The Prospective Pioglitazone
Clinical Trial in Macrovascular Events (PROactive) ob-
served reduced total cardiovascular events, but detected
an increase in HF episodes [83]. Rosiglitazone, however,
was associated with a two-fold increase of incidence of
cardiovascular events as compared with metformin,
which eventually led to its withdrawal from the market
[44]. Consistent with their role as transcriptional regula-
tors of lipid metabolism, the transgenic enhancement of
both PPARα and PPARγ induced a DCM-like phenotype
[58,84]. Such effects have been explained by the reciprocal
repression of glucose uptake and utilization in a setting of
exacerbated lipid use, and may underlie the harmful re-
sponse to the aforementioned PPARγ agonists. Taken as a
whole, PPARα and PPARγ agonisms do not seem to cause
a clinically meaningful benefit on the cardiac outcome of
T2DM patients, and may even aggravate the condition.
New directions against lipid-associated injury
The critical role of PPARs in the regulation of lipid me-
tabolism should not be overlooked, and further research
on different isoforms may suggest future tools against
DCM (Table 3). PPARβ/δ is the most prevalent isoform
in the myocardium and, unlike PPARα, its expression
level is not increased in experimental T2DM [59]. Both
genetic manipulation and selective agonism in mouse
hearts and human cardiac cells provided evidence of the
therapeutic potential of PPARβ/δ against cardiac steatosis,
inflammation and dysfunction [59,85,86]. Such effects
may depend on the ability of PPARβ/δ to up-regulate FA
oxidation enzymes and GLUT4 while limiting FA uptake
and TAG synthesis [59]. Experimental PPARβ/δ activation
also ameliorated dyslipidemia and insulin resistance and
prevented the development of obesity [87]. Thus, it is
plausible that PPARβ/δ-based drugs provide an advan-
tage over current PPARα agonists in the treatment of
the diabetic heart.
Aside from PPARs, several molecular targets are found
modulating lipid metabolism. The genetic manipulation
of molecules involved in the initial steps of lipid absorp-
tion and accumulation has revealed cardioprotective prop-
erties and suggested potential strategies against DCM
(Table 3) [60-62]. From this group, FAT/CD36 is the most
studied molecule and currently has aroused the highest
expectations due to its crucial role in lipotoxicity [88]. Al-
though FAT/CD36 may be responsible for up to 60% of
cardiac FA uptake, the mechanism of FA trafficking across
the sarcolemma is only partially understood. Similar to
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endosomal vesicles and can be translocated upon stimula-
tion by insulin and by contraction. The redistribution of
FAT/CD36 to the sarcolemma is one of the earliest alter-
ations occurring in the heart during diet-induced diabetes,
and has been observed in ZDF rats and in STZ mice in
proportion to the severity of insulin deficiency [89,90].
Consistently, ablation of FAT/CD36 rescued a PPARα
over-expression-induced DCM phenotype [60]. The feasi-
bility of modulating FAT/CD36 was recently addressed by
Glatz et al. in diabetic cardiomyocytes, indicating the
benefit of interfering with FAT/CD36 trafficking [91].
Interestingly, FAT/CD36 was recently shown to be down-
regulated by sitagliptin in db/db mice [30], thus suggesting
that myocardial lipid uptake could also depend upon
GLP-1R signaling. Therefore, modulation of FAT/CD36Figure 1 Metabolic disturbance in the diabetic heart and prospective
dotted lines denote reduced pathway. (1) The therapeutic reduction of FA
oxidative stress, and further improve the energetic yield by shifting metabo
such as PPARβ/δ may provide cardioprotection by down-regulating FA tran
enzymes, and anti-inflammatory transcripts. (3) The elevation of incretin sig
resistance and hyperlipidemia. GLP-1R-dependent actions may include the
and the amelioration of apoptosis and fibrosis. IR, insulin receptor; FA-CoA,may deserve further attention as a prospective etiological
treatment for the diabetic heart.
FAT/CD36 interference may also yield interesting ef-
fects on metabolism-associated inflammation given its
role as Toll-like receptor-4 (TLR4) cofactor [92]. TLRs
are pattern recognition receptors implicated in tailoring
the innate immune cascade through conserved inflamma-
tory pathways. Major cardiac isoforms, TLR4 and TLR2
represent an emerging standpoint for inflammatory and
metabolic coupling in the diabetic heart, where they func-
tion as upstream inducers of NF-κB and regulate insulin
resistance. Notably, ablation of TLR4 and associated li-
gands successfully reverted architectural aberrations and
restored cardiac dysfunction in STZ-treated and non-
obese T1DM (NOD) mice (Table 3) [73-76]. Moreover,
pharmacological intervention of TLR4 has already causedtherapeutic targets. Thickened lines denote activated pathways, and
T/CD36 activity may attenuate myocardial steatosis, inflammation and
lism to glucose utilization. (2) Induction of specific PPAR isoforms
sporters and TAG synthesis and up-regulating GLUT4, β-oxidation
naling by GLP-1 agonists (or DPP-4 inhibitors) may also control insulin
regulation of glucose and FA receptors trafficking to the sarcolemma,
fatty acid-coenzyme A.
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function [93]. It is also known that FAT/CD36 cooperates
with TLR4 to prime the inflammasome, a group of multi-
meric protein complexes of which Nod-like receptor-3
(NLRP3) is the most common form, leading to caspase-1-
mediated IL-1β processing and release [94,95]. Besides
contributing to multiple pro-inflammatory and pro-
fibrotic pathways, NLRP3 has also been shown to pro-
mote insulin resistance. Consistently, NLRP3 knock-
down reduced cardiac hypertrophy and fibrosis and
restored cardiac function in STZ-induced T2DM mice
(Table 3) [37]. This emerging inflammatory perspective
of FAT/CD36 actions reinforces the expectations for its
targeting against DCM.
Genetic engineering has uncovered numerous other
key molecules of lipid metabolism with potential use
against DCM. This group includes rate-limiting lipases
of TAG hydrolysis [63-65], arachidonate lypoxygenases
[66], and mitochondrial enzymes involved in FA synthe-
sis [67-69]. A practical summary of their impact in sev-
eral animal models of DCM is shown in Table 3. There
is also growing interest for the pharmacological utility of
specific peptides regulating energy homeostasis such as
adiponectin and ghrelin. In this regard, genetic enhance-
ment of upstream components of adiponectin signalling
ameliorated DCM phenotype, glucose uptake and cardiac
function in diet-induced T2DM [70,71]. Similar results
were recently described in db/db mice administered desa-
cyl ghrelin, the non-octanoylated form of this “hunger
hormone” [96]. Remarkably, the intervention of some of
these factors achieved functional recovery despite incon-
sistent lowering of cardiac TAG content. In sum, since the
increase of FA oxidation is tightly coupled with higher
rates of oxygen consumption and ROS/RNS generation, it
would seem reasonable to assume that therapies against
lipid uptake will provide advantage over those enhancing
intracellular metabolism. We would also argue that pro-
spective therapies should not focus on reducing the con-
tent of cardiac TAGs but rather prioritize the burden of
derived molecules with greater toxicity such as diacylgly-
cerides and ceramides.
Conclusions
As therapeutic resources currently allow diabetic patients
to manage glucose homeostasis, reach near-normal life ex-
pectancy and delay microvascular complications, it is un-
acceptable that heart-risk reductions are not yet properly
achieved. By targeting DCM we may prevent cardiac func-
tional decline and improve the response to potentially le-
thal coronary events. Although the fine-tune mechanisms
leading to DCM remain partially opaque, restoring cardiac
energy metabolism seem to be a cornerstone. In light of
the experimental data provided here, we may outline a
potential therapeutic strategy focused on correcting theetiological imbalance between lipids and glucose as fuel
substrates (Figure 1). Excessive FA uptake, accumulation,
and utilization may be attenuated by down-modulating
cardiac FAT/CD36 and/or stimulating its transcriptional
regulator PPARβ/δ. Subsequent up-regulation of GLUT4
and glycolitic enzymes would elevate the ATP/O2
-con-
sumption ratio and reduce hyperglycemia and AGE gen-
eration. Insulin resistance and hyperlipidemia may be
also controlled by statins, and perhaps more prospect-
ively by incretin-based drugs, which would balance the
content of sarcolemmal glucose and FA transporters
and exert anti-apoptotic/fibrotic benefits in the cardio-
myocyte. In addition, FAT/CD36 interference may pro-
vide further protection against myocardial inflammation
and stiffness through the attenuation of TLR4-NLRP3
signaling. The design of these cardioprotective plans, how-
ever, may lead to difficulties concerning the possibility of
provoking other end-organ complications associated with
glucotoxicity. To overcome these hurdles, the assessment
of differential traits, stages and pathogenic factors in each
diabetic patient becomes a clinical priority.
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